Management of Insomnia in Patients with Hypertension and Kidney Disease

Non-Pharmacological Interventions

The American Academy of Sleep Medicine recommends Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia, even in patients with comorbidities like hypertension and kidney disease 1, 2
Sleep restriction therapy, which limits time in bed to total sleep time to achieve >85% sleep efficiency, is effective with weekly adjustments based on sleep logs 1
Proper sleep hygiene, including maintaining regular sleep schedules, avoiding stimulants, limiting fluids before bedtime, and using the bedroom only for sleep and sex, is recommended 4
Relaxation techniques such as progressive muscle relaxation, guided imagery, and diaphragmatic breathing can help induce sleep 4

The American Academy of Sleep Medicine recommends low-dose doxepin (3-6mg) for sleep maintenance insomnia with minimal next-day effects 2
Low-dose doxepin improves total sleep time by 26-32 minutes and reduces wake after sleep onset by 22-23 minutes compared to placebo 2
Low-dose doxepin has minimal anticholinergic activity compared to other antidepressants, making it safer for patients with comorbidities 1
The American Geriatrics Society suggests that traditional benzodiazepines, like temazepam, should be used cautiously in patients with kidney disease due to potential accumulation and prolonged effects 4
Eszopiclone may be considered for patients with both sleep onset and maintenance difficulties, improving total sleep time by 28-57 minutes and reducing wake after sleep onset by 10-14 minutes compared to placebo 2

The American Academy of Sleep Medicine and the American Geriatrics Society recommend starting with non-pharmacological approaches, including CBT-I techniques and sleep hygiene education 1, 4
If pharmacological treatment is necessary, low-dose doxepin (3mg initially, may increase to 6mg if needed) is the first choice 2, 1
Eszopiclone 1-2mg may be considered as an alternative for patients with both sleep onset and maintenance issues 2
Monitoring and follow-up should include assessing efficacy and side effects regularly, using the lowest effective dose for the shortest duration necessary, and monitoring kidney function and adjusting dosing as needed 4, 3